Discover. Connect. Capitalize.

Technology Licensing View

4 Technology Views




Phone: (813) 974-0994



2-Acetyl-1,3-Cyclopentanedione for the Treatment of Metabolic Disorders

Researchers at the University of South Florida have recently discovered that use of small molecular weight inhibitors of protein kinase C-zeta and protein kinase C-Lambda/Iota for the treatment of metabolic disorders more specifically for glucose intolerance.

Diabetes is a world wide major cause of morbidity and mortality that is influenced by genetic factors, diet and exercise. Therefore, there is a need to discover a better method for the prevention and treatment of glucose intolerance and related diseases or disorders.

USF inventors have successfully discovered 2-acetyl-1,3-cyclopentanedione (ACDP); ACPD has the potential to completely prevent development of, or reverse or diminish the pre-existing presence of, the diseases aforementioned. The technology is a nov-el, highly specific, potent, small molecular weight inhibitor of both atypical PKCs, PKC-zeta and PKC-lambda/iota. Effective treatment by a single agent for glucose intolerance is promising for treating what is considered the major health concern of modern day.

This technology is directly applicable to the health care and phar-maceutical industries that are involved in the prevention and the treatment of metabolic disorders.

Research Terms: Medical Sciences > Diseases and Disorders > Endocrine Diseases
Keywords: Biosciences, Endocrine System;
Technology Information URL:
University: University of South Florida
Tech Transfer URL:

Associated Patents

Patent Name: Treating an atypical protein kinase C enzyme abnormality
Patent Number: US Patent 9,795,584
Patent Status: Issued
Issue Date: October 24, 2017
Patent Record: View full record at google patents
View full record at United States Patent and Trademark Office
Patent Inventors:

Return to Previous Page

© 1999-2021, State of Florida